Cognition Therapeutics COG0102
Back to Drug Development Trials
![]()
Drug Development Trials
About the trial
A randomized, double-blind, placebo-controlled, phase i study of the safety and pharmacokinetics of two doses of CT1812 in subjects with mild to moderate Alzheimer’s Disease.
